Plasmids, Recombinant Proteins and Antibodies in European CDMO Market

CHALLENGE

A major European private equity firm aimed to gain a comprehensive understanding of the recombinant proteins, antibodies, and plasmid markets, with a specific interest in the CDMO (Contract Development and Manufacturing Organization) landscape in Europe. The firm wanted to explore market dynamics, technical challenges, and business opportunities, particularly in the area of plasmid production.

BTHT APPROACH

BTHT developed a tailored research strategy to engage top-tier experts with specialized knowledge in the relevant fields. Our focus was on identifying professionals with extensive experience in recombinant proteins, antibodies, and plasmid production from both the pharmaceutical and CDMO sectors. We assembled a diverse group of experts, including:

• Head of Process Development / Cell-lines Development / MSAT with expertise in the technical aspects of plasmid production and biotechnological advancements.
• Business Development Directors with insights into market trends and strategic business practices within the CDMO sector.
• Former CEO from both customer and competitor side who could provide perspectives on enhancing production processes and operational efficiencies.
• Sr. Director, Global Biologics Testing Sales offering a comprehensive view of the technical and strategic considerations for the topic.
• Global Program Development Leaders with experience managing significant projects in the pharmaceutical and biotech fields.

BTHT organized one-hour consultations, facilitating focused and effective discussions between the client and these experts, ensuring smooth communication without technical issues.

OUTCOME

BTHT's expert-led approach delivered deep insights into the European recombinant proteins, antibodies, and plasmid markets, highlighting both the pharmaceutical and CDMO sectors. The consultations provided the private equity firm with valuable information on market dynamics, technical obstacles, and potential business opportunities. This allowed the client to refine their investment strategies, enhance their strategic planning, and pinpoint key areas for growth and innovation within the biotech industry.